These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 875057)

  • 1. Pepstatin, an ascites retardant of L1210 tumor-bearing mice.
    Greenbaum LM; Semente G
    J Natl Cancer Inst; 1977 Jul; 59(1):259-62. PubMed ID: 875057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further studies of the effect of pepstatin on ascites accumulation in tumor-bearing mice.
    Greenbaum LM; Esumi H; Sato S
    Cancer Lett; 1979 Jul; 7(2-3):91-6. PubMed ID: 476614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pepstatin, an inhibitor of leukokinin formation and ascitic fluid accumulation.
    Greenbaum LM; Grebow P; Johnston M; Prakash A; Semente G
    Cancer Res; 1975 Mar; 35(3):706-10. PubMed ID: 46779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscle aspartyl protease (cathepsin D) activity: detection using a chromophoric substrate and relation to wasting in DBA/2 mice implanted with leukemic L1210 tumor cells.
    Bolger GT; Jaramillo J
    Can J Physiol Pharmacol; 1996 Oct; 74(10):1141-8. PubMed ID: 9022834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pepstatin, an inhibitor of acid kininogenases and ascites retardant in neoplastic disease.
    Greenbaum LM
    Fed Proc; 1979 Dec; 38(13):2788-91. PubMed ID: 92421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical effects and therapeutic potential of tunicamycin in murine L1210 leukemia.
    Morin MJ; Bernacki RJ
    Cancer Res; 1983 Apr; 43(4):1669-74. PubMed ID: 6339042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of E-64 (cysteine-proteinase inhibitor) and pepstatin (aspartyl-proteinase inhibitor) on metastasis formation in mice with mammary and ovarian tumors.
    Leto G; Pizzolanti G; Tumminello FM; Gebbia N
    In Vivo; 1994; 8(2):231-6. PubMed ID: 7919127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of variations in the cell population kinetics with tumor age in the L1210 ascites tumor.
    Dombernowsky P; Hartmann NR
    Cancer Res; 1972 Nov; 32(11):2452-8. PubMed ID: 5082593
    [No Abstract]   [Full Text] [Related]  

  • 9. Host cathepsin D response to tumor in the normal and pepstatin-treated mouse.
    Greenbaum LM; Sutherland JH
    Cancer Res; 1983 Jun; 43(6):2584-7. PubMed ID: 6850578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritoneal macrophage response to leukemia L1210 in syngeneic mice.
    Berd D; Prehn RT
    J Natl Cancer Inst; 1977 Jun; 58(6):1729-34. PubMed ID: 864751
    [No Abstract]   [Full Text] [Related]  

  • 11. Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high-dose methotrexate in murine tumor models.
    Sirotnak FM; Donsbach RC; Dorick DM; Moccio DM
    Cancer Res; 1976 Dec; 36(12):4672-8. PubMed ID: 1000510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice.
    Ohnishi H; Lin KM; Chu TM
    Cancer Res; 1990 Feb; 50(4):1107-12. PubMed ID: 2297759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
    Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
    Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of VM-26 on the haematological responses of mice to L1210 leukaemia.
    Hacker M; Roberts D; Jackson CW
    Br J Cancer; 1980 Nov; 42(5):697-702. PubMed ID: 7459207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of dog renin activity by pepstatin A.
    Miyazaki M; Komori T; Okunishi H; Toda N
    Jpn Circ J; 1979 Sep; 43(9):818-23. PubMed ID: 501901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of in vivo inhibition of tissue cathepsin D by pepstatin A.
    Leto G; Tumminello FM; Gebbia N; Rausa L
    Int J Biochem; 1988; 20(9):917-20. PubMed ID: 3197907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
    Avery TL; Roberts D
    Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimetastatic activity of adriamycin in combinations with proteinase inhibitors in mice.
    Leto G; Tumminello FM; Gebbia N; Woynarowska B; Bernacki RJ
    Anticancer Res; 1990; 10(1):265-9. PubMed ID: 2334138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rescue of thymidine cytotoxicity in L1210 ascites by elevated endogenous levels of deoxycytidine.
    Egan EM; Sargent L; Rosowsky A; Kufe DW
    Cancer Treat Rep; 1981; 65(9-10):853-60. PubMed ID: 7273018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumour activity of 1-naphthol against L1210 leukaemia in vivo and Ehrlich ascites tumour cells in vivo and in vitro.
    Jones M; d'Arcy Doherty M; Cohen GM
    Cancer Lett; 1986 Dec; 33(3):347-54. PubMed ID: 3802063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.